Chiesi Group Selects Salesforce Agentforce Life Sciences to Transform Customer Engagement

SAN FRANCISCO and PARMA, ITALY - April 20, 2026 - Chiesi Group, an international biopharmaceutical group, has selected Salesforce's Agentforce Life Sciences for Customer Engagement to transform its commercial operations and strengthen engagement with healthcare professionals worldwide.

Chiesi's implementation of Agentforce Life Sciences marks a step-change in how it supports patients and healthcare professionals, bringing a more connected and responsive way of working across the organization. By moving to a unified platform, Chiesi is enabling its teams to act faster, collaborate more effectively, and focus on meaningful customer centric engagement. This innovation will empower employees with actionable insights, enhance interactions with healthcare professionals, and ultimately help build a more agile foundation for sustainable growth and deliver better outcomes for patients, while ensuring full compliance with pharmaceutical and privacy legislations as well as with responsible Artificial Intelligence standards.

Headquartered in Parma and now in its third generation of family leadership with more than 30 affiliates worldwide, Chiesi exports to more than 100 countries. A Benefit Corporation and a certified B Corp, Chiesi integrates business performance with social and environmental responsibility, embedding long-term value creation into its operating model. In 2024, the company reinvested 24% of its revenues into R&D - underscoring its strong innovation focus.

Building an end-to-end commercial ecosystem

Chiesi's decision follows a strategic review of its digital roadmap, focused on strengthening its ability to operate and grow in an increasingly complex and regulated global environment that could benefit from further modernization. The company identified key opportunities to enhance how it supports patients and healthcare professionals, while improving the effectiveness of its teams across commercial operations, scientific R&D and global manufacturing.

Chiesi will leverage Salesforce's platform to achieve:

• Unified Data Foundation with Data 360 : Chiesi will consolidate customer data to build a single, trusted view of healthcare professionals, hospitals, and pharmacies. Data 360 serves as the foundational layer that brings together field interactions, medical affairs activities, and business operations, ensuring teams across markets have access to consistent, compliant customer information.
• Agentforce Powered Field Teams: Field representatives across Chiesi's global markets will be supported by Agentforce in preparing for customer visits with AI-assisted suggestions and summaries that help streamline everyday tasks such as note drafting and cycle planning. This frees up time to focus on meaningful conversations with healthcare providers.
• Commercial Operations at Scale: With Agentforce Life Sciences for Customer Engagement, Chiesi's teams will manage the full lifecycle from HCP engagement and event coordination to multichannel campaigns powered by Agentforce Marketing.

Accelerating digital transformation in a changing industry

The pharmaceutical industry is navigating increasing geopolitical, regulatory and supply chain pressures while the way healthcare professionals engage with information continues to evolve across multiple channels. This has reinforced the need for organizations to operate with greater agility, resilience and readiness.

Chiesi's leadership recognizes that transformation is essential to remain competitive in this evolving landscape. The company is prioritizing the strengthening of its core business, while taking a measured, science-led approach to innovation-gradually introducing AI as a supportive enabler that enhances decision-making, empowers employees, and improves engagement with healthcare professionals, ultimately delivering greater value for patients.

Fabio Mira, Senior VP, Chief Transformation Officer, Chiesi Group, said: "At Chiesi, this transformation is about strengthening how we serve patients and healthcare professionals, while enabling our teams to work in more connected and effective ways. By building a unified commercial ecosystem with Salesforce Agentforce Life Sciences, we are creating a strong foundation for sustainable growth, greater agility, and long-term value."

A Strategic Shift for Life Sciences in Italy and Beyond

"Chiesi's selection of Salesforce signals a transformative shift for the life sciences industry in Italy and globally," said Joe Ferraro, SVP and GM of Agentforce Life Sciences. "This partnership demonstrates that pharmaceutical companies are ready to move beyond legacy CRM systems and embrace AI-native platforms that deliver true commercial transformation. With 3,300 users, Chiesi is setting a new standard for how modern life sciences companies leverage Agentforce, Data 360, and Marketing Cloud together to create unified customer experiences and drive measurable business outcomes."

Vanessa Fortarezza, Country Manager, Salesforce Italy, said: "Chiesi embodies the present and future of Italian innovation: globally competitive, research-driven and purpose-led. This partnership demonstrates how forward-thinking pharmaceutical companies are moving beyond legacy systems to create resilient, data-driven ecosystems. Together, we are building a foundation that will enable Chiesi to scale AI capabilities responsibly and effectively over time."

Fabio Mira also added: "This is, first and foremost, a people-led transformation. Together with Salesforce, we are building a true partnership that goes beyond technology, focused on empowering our employees with the tools, insights, and support they need to create more meaningful connections with healthcare professionals. By working hand-in-hand, we are ensuring this transformation delivers real, lasting impact for our teams and ultimately better outcomes for patients."

Learn more:

About Chiesi Group

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment. By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi's commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi meets verified standards for social and environmental business practices. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group's research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For more information, visit chiesi.com.